Pharma Plays Balancing Act with US Democrats After Drug Pricing Reform Passes

While pharma mulls over how to fight back over the new US drug pricing reforms, they are carefully weighing how to navigate negotiations with Democrats. Lawsuits have already been filed, but the timeline for those is yet to be determined, so the industry can’t be too hardball with the party if it maintains power after the midterm elections next month.

According to Axios, “Manufacturers have a multi-pronged strategy that calls for follow-on legislation to soften the financial blow, shaping regulations that spell out how the law will be implemented and even filing lawsuits challenging the government’s authority to control prices, industry sources say.”

To read more, click here.

(Source: Axios, October 4^th, 2022)